Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies.

Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, Jocham D, Ziegler A, Vonthein R.

Eur Urol. 2010 Apr;57(4):595-606. doi: 10.1016/j.eururo.2009.11.041. Epub 2009 Dec 2. Review.

PMID:
20004052
2.

Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.

Witjes JA, Redorta JP, Jacqmin D, Sofras F, Malmström PU, Riedl C, Jocham D, Conti G, Montorsi F, Arentsen HC, Zaak D, Mostafid AH, Babjuk M.

Eur Urol. 2010 Apr;57(4):607-14. doi: 10.1016/j.eururo.2010.01.025. Epub 2010 Jan 22. Review.

PMID:
20116164
3.

Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.

Rink M, Babjuk M, Catto JW, Jichlinski P, Shariat SF, Stenzl A, Stepp H, Zaak D, Witjes JA.

Eur Urol. 2013 Oct;64(4):624-38. doi: 10.1016/j.eururo.2013.07.007. Epub 2013 Jul 19. Review.

PMID:
23906669
4.

Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.

Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, Mariappan P, Palou Redorta J, Stenzl A, van Velthoven R, Zaak D.

Eur Urol. 2014 Nov;66(5):863-71. doi: 10.1016/j.eururo.2014.06.037. Epub 2014 Jul 4. Review.

PMID:
25001887
5.

[Fluorescence diagnosis in patients with non-muscle invasive bladder cancer: results of a metaanalysis].

Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, Jocham D, Ziegler A, Vonthein R.

Aktuelle Urol. 2010 May;41(3):171-7. doi: 10.1055/s-0030-1247363. Epub 2010 May 18. German.

PMID:
20486035
6.

Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid.

Drăgoescu O, Tomescu P, Pănuş A, Enache M, Maria C, Stoica L, Pleşea IE.

Rom J Morphol Embryol. 2011;52(1):123-7.

7.

Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.

Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, Ray E, Fradet Y, Karl A, Burgués JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D.

Eur Urol. 2013 Nov;64(5):846-54. doi: 10.1016/j.eururo.2013.03.059. Epub 2013 Apr 8. Review.

PMID:
23602406
8.

Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.

Burger M, Stief CG, Zaak D, Stenzl A, Wieland WF, Jocham D, Otto W, Denzinger S.

Urology. 2009 Dec;74(6):1282-6. doi: 10.1016/j.urology.2009.06.088. Epub 2009 Oct 12.

PMID:
19819538
9.

Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?

Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, Geavlete P.

BJU Int. 2012 Feb;109(4):549-56. doi: 10.1111/j.1464-410X.2011.10374.x. Epub 2011 Jun 28.

10.

The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer.

Bunce C, Ayres BE, Griffiths TR, Mostafid H, Kelly J, Persad R, Kockelbergh R.

BJU Int. 2010 Feb;105 Suppl 2:2-7. doi: 10.1111/j.1464-410X.2009.09150.x. Review. No abstract available.

11.

Improved detection and reduced early recurrence of non-muscle-invasive bladder cancer using hexaminolaevulinate fluorescence cystoscopy: results of a multicentre prospective randomized study (PC B305).

Mostafid H, Bunce C; Action on Bladder Cancer Group.

BJU Int. 2009 Oct;104(7):889-90. doi: 10.1111/j.1464-410X.2009.08691.x. Epub 2009 Jun 22. No abstract available.

12.

[Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer].

Danil'chenko DI, Koenig F, Riedl K, Schnorr D, Waldman A, Al-Shukri S, Loening SA.

Vopr Onkol. 2003;49(6):734-7. Russian.

PMID:
14976918
13.

Editorial comment.

Scarpa RM, Cracco CM.

Urology. 2009 Dec;74(6):1286-7; author reply 1287-8. doi: 10.1016/j.urology.2009.08.033. No abstract available.

PMID:
19962530
14.

[Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group].

Burgués JP, Conde G, Oliva J, Abascal JM, Iborra I, Puertas M, Ordoño F; Grupo BLUE (Blue Light Urologic Endoscopy).

Actas Urol Esp. 2011 Sep;35(8):439-45. doi: 10.1016/j.acuro.2011.03.003. Epub 2011 May 28. Spanish.

PMID:
21621301
15.

Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.

Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M.

J Urol. 2012 Jul;188(1):58-62. doi: 10.1016/j.juro.2012.03.007. Epub 2012 May 12.

16.

Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.

Yang LP.

Mol Diagn Ther. 2014 Feb;18(1):105-16. doi: 10.1007/s40291-013-0068-x. Review.

PMID:
24248555
17.

A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study.

Lapini A, Minervini A, Masala A, Schips L, Pycha A, Cindolo L, Giannella R, Martini T, Vittori G, Zani D, Bellomo F, Cosciani Cunico S.

Surg Endosc. 2012 Dec;26(12):3634-41. doi: 10.1007/s00464-012-2387-0. Epub 2012 Jun 23.

PMID:
22729704
18.

Blue-sky thinking about blue-light cystoscopy.

Thomas K, O'Brien T.

BJU Int. 2009 Oct;104(7):887-9. doi: 10.1111/j.1464-410X.2009.08713.x. Epub 2009 Jul 2. No abstract available.

19.

Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate.

Stanislaus P, Zaak D, Stadler T, Tritschler S, Knüchel R, Stief CG, Karl A.

World J Urol. 2010 Aug;28(4):407-11. doi: 10.1007/s00345-010-0574-y. Epub 2010 Jun 26.

PMID:
20582546
20.

Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer.

Sievert KD, Kruck S.

Expert Rev Anticancer Ther. 2009 Aug;9(8):1055-63. doi: 10.1586/era.09.73. Review.

PMID:
19671025
Items per page

Supplemental Content

Write to the Help Desk